Revolution Medicines R&D President Steve Kelsey to Transition to Senior Advisor, Retire January 2027
Revolution Medicines announced that Steve Kelsey, president of research and development, will transition to senior advisor to the CEO ahead of his planned retirement in January 2027. The company said it will implement a new R&D leadership structure to support continued execution of its strategy but did not provide details on the new structure or name Kelsey's successor.
Revolution Medicines announced that Steve Kelsey, president of research and development, will transition to senior advisor to the CEO ahead of his planned retirement in January 2027. The company said it will implement a new R&D leadership structure to support continued execution of its strategy.
Revolution Medicines is a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers. Kelsey's departure removes the executive leading pipeline development at a stage when late-phase trial execution and regulatory preparation typically accelerate.
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.